Outlook Therapeutics Inc (NASDAQ:OTLK) price on Friday, April 11, rose 11.29% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.38.
A look at the stock’s price movement, the close in the last trading session was $1.24, moving within a range at $1.2 and $1.39. The beta value (5-Year monthly) was 0.472. Turning to its 52-week performance, $9.34 and $0.87 were the 52-week high and 52-week low respectively. Overall, OTLK moved -6.76% over the past month.
Outlook Therapeutics Inc’s market cap currently stands at around $45.02 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-13.
Turning to the stock’s technical picture we see that short term indicators suggest on average that OTLK is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 5 recommend OTLK as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
OTLK’s current price about 3.70% and -8.29% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 51.00, while 7-day volatility ratio is 13.82% and 10.01% in the 30-day chart. Further, Outlook Therapeutics Inc (OTLK) has a beta value of 0.42, and an average true range (ATR) of 0.13.
If we refocus on Outlook Therapeutics Inc (NASDAQ:OTLK), historical trading data shows that trading volumes averaged 0.43 over the past 10 days and 574.65K over the past 3 months. The company’s latest data on shares outstanding shows there are 24.91 million shares.
The 37.11% of Outlook Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 16.25% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 3.93 million on 2025-03-14, giving us a short ratio of 8.45. The data shows that as of 2025-03-14 short interest in Outlook Therapeutics Inc (OTLK) stood at 1625.0 of shares outstanding, with shares short rising to 3.53 million registered in 2025-02-14. Current price change has pushed the stock -26.98% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the OTLK stock continues to rise going into the next quarter.
